Inotiv Inc. (BS50)

Overview

Inotiv, Inc. is a prominent provider of nonclinical and analytical drug discovery and development services catering to the pharmaceutical and medical device industries. With a comprehensive approach divided into two main segments: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS), Inotiv's extensive offerings support the entire lifecycle of drug and device development. Originating as Bioanalytical Systems, Inc., the company underwent a rebranding in March 2021 to better reflect its broadened scope and capabilities. Established in 1974 and based in West Lafayette, Indiana, Inotiv has expanded its footprint to include operations in the United States, the Netherlands, and various international locations, ensuring a global reach in its service provision.

Products and Services

• Research and Discovery Services

  Including computational toxicology, disease pharmacology, DMPK (Drug Metabolism and Pharmacokinetics), safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device services, and cell and molecular biology. These services are crucial for identifying and validating new drug targets, understanding the pharmacokinetic profiles of compounds, and evaluating their safety and efficacy.

• Non-clinical Safety Assessment

  Comprehensive assessments covering general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and developmental and reproductive toxicology. These assessments are essential for determining the safety profile of new compounds and supporting regulatory submissions.

• Pathology Services

  Offering histology, digital, clinical, and medical device pathology services. Such services provide crucial information on the effects of drug compounds on body tissues, helping to elucidate mechanisms of action and identify potential adverse effects.

• Bioanalysis

  Including non-regulated discovery bioanalysis, biotherapeutics characterization, and regulated preclinical and clinical bioanalysis. Bioanalytical services are vital for quantifying drugs and their metabolites in biological samples, supporting the development and validation of bioanalytical methods.

• Proteomics

  This service involves the large-scale study of proteins, including their expression, functions, and structures, which is integral to understanding disease mechanisms and identifying potential therapeutic targets.

• Consulting Services

  Providing expert advice on a range of topics, including regulatory strategy, drug development planning, and scientific and technical guidance. These services are crucial for navigating the complex regulatory landscape and ensuring the efficient progression of drugs through the development pipeline.

• Model and Research Services

  Engages in the commercial production and sales of research models, diets, bedding, and bioproducts. These services support the research community with high-quality models and products necessary for conducting preclinical research.